Tempus AI, Inc. (TEM)

Tempus AI, Inc. is a healthcare technology company that develops what it terms "Intelligent Diagnostics" by applying artificial intelligence, including generative and agentic AI, to laboratory testing and precision medicine. The company's core innovation connects laboratory test results—genomic and otherwise—to a patient's broader clinical data, thereby contextualizing results based on individual patient characteristics to guide therapy selection, clinical trial matching, and treatment decisions. Its proprietary Tempus Platform combines a technology infrastructure for breaking down healthcare data silos with an operating system that structures and harmonizes multimodal data (molecular, clinical, imaging, and outcomes data), creating one of the largest libraries of matched clinical and molecular oncology data in the world.

The company operates through more than 700 unique data connections across roughly 5,000 healthcare institution sites, reaching over 55% of U.S. oncologists and more than 65% of U.S. academic medical centers. Tempus organizes its offerings into two product lines: Diagnostics, which includes Oncology and Hereditary testing businesses providing next-generation sequencing (NGS), PCR profiling, and anatomic/molecular pathology testing; and Data and Applications, which includes Insights (licensing de-identified multimodal data libraries with analytic tools to pharmaceutical and biotechnology companies), Trials (clinical trial matching and support leveraging its oncology physician network), Next (an AI platform identifying care gaps in oncology and cardiology patients), and Algos (algorithmic diagnostics such as TO, HRD, DPYD, and Tempus Purist). These two product lines are designed to reinforce one another, creating network effects where growing datasets improve test accuracy, attract more physicians and applications, and further expand the database's value for both clinical care and research.

While oncology remains its primary focus, the company is expanding into additional disease areas including neurology and cardiology, and pursuing international growth through initiatives such as its SB Tempus Corp. joint venture in Japan. Tempus has also pursued acquisitions to expand capabilities and data assets, including Paige.AI, Inc., Ambry Genetics Corporation, and Deep 6 AI, Inc. The company positions itself uniquely at the intersection of healthcare and technology, differentiating itself from traditional diagnostic labs by incorporating multimodal patient data into testing, and from other technology companies through its deep roots in direct clinical care delivery as one of the largest sequencers of cancer patients in the United States.